Related Experiment Video
Updated: Aug 15, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Emerging biologic drugs for the treatment of rheumatoid arthritis
Francesco Puppo1, Giuseppe Murdaca, Massimo Ghio
1Department of Internal Medicine (Di.M.I.), University of Genoa, Viale Benedetto XV, n.6-16132 Genova, Italy. puppof@unige.it
Abstract:
This article reviews the role of emerging biologic drugs for the treatment of rheumatoid arthritis (RA). Besides anti-tumor necrosis factor (TNF)-alpha and anti-interleukin (IL)-1 agents (Infliximab, Adalimumab, Etanercept and Anakinra) whose clinical efficacy is now established, new drugs have been proposed for the therapy of rheumatoid arthritis patients not responding to conventional treatments. These approaches include the blockade of B-cell activity with anti-CD20 monoclonal antibody (Rituximab) and the inhibition of T-cell activation with fusion protein CTLA4Ig. Moreover, promising results have been obtained in animal models utilizing suppressors of cytokine signaling (SOCS) and dominant-negative TNF variants to inactivate TNF signaling.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug Products: Biologics, Biosimilars and Interchangeables
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
